• Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (CelloPub=CLPUB00604).
  
• Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604).
  

PubMed=7949178; DOI=10.1182/blood.V84.9.3063.3063
Hardin J., MacLeod S.L., Grigorieva I., Chang R.-X., Barlogie B., Xiao H.-Q., Epstein J.
Interleukin-6 prevents dexamethasone-induced myeloma cell death.
Blood 84:3063-3070(1994)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=14555701
Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Mol. Cancer Ther. 2:825-833(2003)

PubMed=14760100; DOI=10.1158/1078-0432.CCR-0793-03
Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H., Anderson K.C., Munshi N.C.
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.
Clin. Cancer Res. 10:770-776(2004)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017); University of Toronto; Toronto; Canada

PubMed=29045832; DOI=10.1016/j.celrep.2017.09.078; PMCID=PMC5706555
Ezponda T., Dupere-Richer D., Will C.M., Small E.C., Varghese N., Patel T., Nabet B., Popovic R., Oyer J., Bulic M., Zheng Y.-P., Huang X.-X., Shah M.Y., Maji S., Riva A., Occhionorelli M., Tonon G., Kelleher N.L., Keats J.J., Licht J.D.
UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition.
Cell Rep. 21:628-640(2017)